Skip to main content
Premium Trial:

Request an Annual Quote

DiaSorin Gets FDA 510(k) Clearance for Molecular CMV Test

NEW YORK — Italian diagnostics firm DiaSorin said on Wednesday that it has received 510(k) clearance from the US Food and Drug Administration for its Simplexa Congenital CMV Direct kit for the detection of cytomegalovirus (CMV) DNA.

Congenital CMV occurs when the virus is passed from mother to child, resulting in potentially fatal outcomes. The test, which runs on DiaSorin's Liaison MDx instrument, is designed to detect CMV DNA in both saliva swab and urine specimens from newborns 21 days old or younger.

"The Simplexa Congenital CMV Direct kit is the first FDA-cleared product for diagnosing congenital CMV from both saliva swab and urine specimens," DiaSorin CSO Michelle Tabb said in a statement. "This allows accurate and fast diagnosis with one test enabling early intervention and treatment."

The test received CE marking in mid-2020.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.